In addition, OS of pan-cancer patients (n=9384) without CDKN2A deletion was longer than those (n=1418) with CDKN2A deletion in TCGA project (p<0.001; Figure 2E and Data File 2) (6, 7, 31–33). Here, CDKN2A is linked to cancer.